{"id":10242,"date":"2024-07-30T10:37:53","date_gmt":"2024-07-30T10:37:53","guid":{"rendered":"https:\/\/www.dhenne-avocats.fr\/?p=10242"},"modified":"2026-10-23T16:32:01","modified_gmt":"2026-10-23T16:32:01","slug":"sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques","status":"publish","type":"post","link":"https:\/\/www.dhenne-avocats.fr\/ja\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","title":{"rendered":"Sanofi c. Amgen\uff1aUPC\u521d\u306e\u7121\u52b9\u8a34\u8a1f\u3068\u6cbb\u7642\u7528\u6297\u4f53\u306e\u7279\u8a31\u6027"},"content":{"rendered":"<p><br \/>\n<br \/>\n<\/p>\n<p><em>2026\u5e748\u670830\u65e5\u66f4\u65b0<\/em><\/p>\n<p>2024\u5e747\u670816\u65e5\u3001\u7d71\u4e00\u7279\u8a31\u88c1\u5224\u6240\uff08UPC\uff09\u306e\u30df\u30e5\u30f3\u30d8\u30f3\u4e2d\u592e\u90e8\u306f\u3001\u521d\u3081\u3066\u6b27\u5dde\u7279\u8a31\u3092\u7121\u52b9\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002\u6297PCSK9\u6297\u4f53\u306b\u95a2\u3059\u308bAmgen\u306e\u7279\u8a31EP 3 666 797\u306f\u3001\u3053\u306e\u65b0\u305f\u306a\u88c1\u5224\u6240\u306b\u304a\u3044\u3066\u521d\u3081\u3066\u8a8d\u5bb9\u3055\u308c\u305f\u7121\u52b9\u8a34\u8a1f\uff08UPC_CFI_1\/2023\uff09\u306b\u3088\u308a\u5931\u52b9\u3059\u308b\u3053\u3068\u3068\u306a\u3063\u305f\u306e\u3067\u3059\u3002<\/p>\n<p>\u305d\u306e\u5f8c\u3001\u4e8b\u614b\u306f\u9006\u8ee2\u3057\u307e\u3057\u305f\u30022025\u5e7411\u670825\u65e5\u3001UPC\u306e\u63a7\u8a34\u88c1\u5224\u6240\u306f\u3053\u306e\u5224\u65ad\u3092\u7834\u68c4\u3057\u3001\u7279\u8a31\u3092\u7dad\u6301\u3057\u307e\u3057\u305f\u3002\u540c\u3058\u7279\u8a31\u3001\u540c\u3058\u5148\u884c\u6280\u8853\u3067\u3042\u308a\u306a\u304c\u3089\u3001\u6b63\u53cd\u5bfe\u306e\u4e8c\u3064\u306e\u7d50\u8ad6\u304c\u793a\u3055\u308c\u305f\u306e\u3067\u3059\u3002\u4e21\u5be9\u7d1a\u306e\u9593\u3067\u4e89\u308f\u308c\u305f\u306e\u306f\u3001\u307e\u3055\u306b\u6cbb\u7642\u7528\u6297\u4f53\u306e<a href=\"\/ja\/lexique-propriete-intellectuelle\/activite-inventive\/\">\u9032\u6b69\u6027<\/a>\u306e\u8a55\u4fa1\u3068\u3044\u3046\u554f\u984c\u305d\u306e\u3082\u306e\u3067\u3057\u305f\u3002<\/p>\n<p>\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u306e\u7279\u8a31\u30dd\u30fc\u30c8\u30d5\u30a9\u30ea\u30aa\u3092\u6709\u3059\u308b\u6a29\u5229\u8005\u306b\u3068\u3063\u3066\u3082\u3001\u3053\u308c\u306b\u6311\u3080\u5074\u306b\u3068\u3063\u3066\u3082\u3001\u3053\u306e\u4e00\u9023\u306e\u8a34\u8a1f\u306f\u3001\u6025\u901f\u306b\u5f62\u6210\u3055\u308c\u3064\u3064\u3042\u308b<a href=\"\/ja\/deux-ans-de-jub-une-lecture-critique-et-juridique-de-la-juridiction-unifiee-du-brevet\/\">UPC\u306e\u5224\u4f8b<\/a>\u306e\u4e2d\u3067\u3001\u6297\u4f53\u306e\u7279\u8a31\u6027\u306b\u95a2\u3059\u308b\u6b27\u5dde\u306e\u57fa\u6e96\u3092\u5b9a\u3081\u308b\u3082\u306e\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<h2>PCSK9\u8a34\u8a1f\uff1a\u4e16\u754c\u898f\u6a21\u306e\u7d1b\u4e89<\/h2>\n<p>\u672c\u4ef6\u306f\u3001\u30a8\u30dc\u30ed\u30af\u30de\u30d6\uff08Repatha\u00ae\uff09\u3092\u30ab\u30d0\u30fc\u3059\u308bAmgen\u306e\u7279\u8a31\u3092\u3081\u3050\u308a\u3001Sanofi\u3068Regeneron\u304c\u8ca9\u58f2\u3059\u308b\u30a2\u30ea\u30ed\u30af\u30de\u30d6\uff08Praluent\u00ae\uff09\u306b\u5bfe\u3057\u30662014\u5e74\u304b\u3089\u7d9a\u304f\u5bfe\u7acb\u306e\u4e00\u74b0\u3092\u306a\u3059\u3082\u306e\u3067\u3059\u3002\u3053\u306e\u7d1b\u4e89\u306f\u8907\u6570\u306e\u5927\u9678\u306b\u5e83\u304c\u308a\u30012023\u5e745\u6708\u306b\u306f\u7c73\u56fd\u9023\u90a6\u6700\u9ad8\u88c1\u5224\u6240\u304c\u3001\u5b9f\u65bd\u53ef\u80fd\u8981\u4ef6\uff08enablement\uff09\u306e\u4e0d\u5099\u3092\u7406\u7531\u3068\u3057\u3066Amgen\u306e\u7c73\u56fd\u7279\u8a31\u306e\u8acb\u6c42\u9805\u3092\u7121\u52b9\u3068\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>UPC\u304c\u958b\u8a2d\u3055\u308c\u305f2023\u5e746\u67081\u65e5\u306e\u6642\u70b9\u3067\u3001Sanofi\u3068Regeneron\u306f\u30df\u30e5\u30f3\u30d8\u30f3\u4e2d\u592e\u90e8\u306b\u7279\u8a31EP 3 666 797\u306e\u7121\u52b9\u8a34\u8a1f\u3092\u63d0\u8d77\u3057\u3001\u4ed6\u65b9Amgen\u306f\u30df\u30e5\u30f3\u30d8\u30f3\u5730\u65b9\u90e8\u306b\u4fb5\u5bb3\u8a34\u8a1f\u3092\u63d0\u8d77\u3057\u307e\u3057\u305f\u3002\u3053\u3053\u304b\u3089\u3001\u540c\u88c1\u5224\u6240\u306e\u6b74\u53f2\u4e0a\u521d\u306e<a href=\"\/ja\/lexique-propriete-intellectuelle\/annulation-du-brevet\/\">\u7279\u8a31\u306e\u7121\u52b9<\/a>\u304c\u751f\u307e\u308c\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002<\/p>\n<h2>2024\u5e747\u670816\u65e5\uff1aUPC\u306b\u3088\u308b\u521d\u306e\u7121\u52b9\u5224\u65ad<\/h2>\n<p>\u4e2d\u592e\u90e8\u306f\u307e\u305a\u3001\u6587\u8a00\u3092\u53b3\u683c\u306b\u6a5f\u80fd\u7684\u306b\u89e3\u91c8\u3059\u308b\u7acb\u5834\u3092\u9000\u3051\u307e\u3057\u305f\u3002\u6392\u4ed6\u7684\u306a\u7d50\u5408\u90e8\u4f4d\u304c\u660e\u78ba\u306b\u793a\u3055\u308c\u3066\u3044\u306a\u3044\u4ee5\u4e0a\u3001\u5f53\u696d\u8005\u306f\u3001\u5f53\u8a72\u8acb\u6c42\u9805\u304cPCSK9\u306e\u89e6\u5a92\u30c9\u30e1\u30a4\u30f3\u306b\u7d50\u5408\u3059\u308b\u3059\u3079\u3066\u306e\u6297\u4f53\u3092\u30ab\u30d0\u30fc\u3059\u308b\u3082\u306e\u3068\u306f\u7406\u89e3\u3057\u306a\u304b\u3063\u305f\u3067\u3042\u308d\u3046\u3001\u3068\u3044\u3046\u306e\u3067\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u4e2d\u592e\u90e8\u306f\u3001\u89e3\u91c8\u306b\u304a\u3044\u3066\u660e\u7d30\u66f8\u306b\u5927\u304d\u306a\u6bd4\u91cd\u3092\u8a8d\u3081\u3001\u5f53\u6642\u306e\u6b27\u5dde\u7279\u8a31\u5e81\uff08EPO\uff09\u3067\u652f\u914d\u7684\u3067\u3042\u3063\u305f\u5b9f\u52d9\u304b\u3089\u8ddd\u96e2\u3092\u7f6e\u304d\u307e\u3057\u305f\u3002<\/p>\n<p>\u9032\u6b69\u6027\u306b\u3064\u3044\u3066\u306f\u3001\u4e2d\u592e\u90e8\u306f\u5f93\u6765\u306e\u8ab2\u984c\u89e3\u6c7a\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u63a1\u3089\u305a\u3001\u5148\u884c\u6280\u8853\u306b\u304a\u3051\u308b\u300c\u73fe\u5b9f\u7684\u306a\u51fa\u767a\u70b9\u300d\u306b\u4f9d\u62e0\u3057\u307e\u3057\u305f\u3002\u5148\u884c\u6280\u8853\u304cPCSK9\u3068LDLR\u306e\u76f8\u4e92\u4f5c\u7528\u3092\u963b\u5bb3\u3059\u308b\u6297\u4f53\u3078\u3068\u660e\u793a\u7684\u306b\u65b9\u5411\u3065\u3051\u3066\u3044\u305f\u3053\u3068\u3092\u8a8d\u5b9a\u3057\u305f\u3046\u3048\u3067\u3001\u5f53\u696d\u8005\u306b\u306f\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u304c\u3042\u308a\u3001\u5fc5\u8981\u3068\u3055\u308c\u308b\u4f5c\u696d\u304c\u81a8\u5927\u3067\u3042\u3063\u3066\u3082\u9032\u6b69\u7684\u306a\u52aa\u529b\u306f\u8981\u3057\u306a\u304b\u3063\u305f\u3068\u7d50\u8ad6\u3065\u3051\u307e\u3057\u305f\u3002\u65e2\u77e5\u306e\u6a19\u7684\u306b\u5bfe\u3059\u308b\u6297\u4f53\u306e\u958b\u767a\u306f\u3001\u30eb\u30fc\u30c6\u30a3\u30f3\u306e\u7bc4\u56f2\u306b\u5c5e\u3059\u308b\u3068\u3044\u3046\u308f\u3051\u3067\u3059\u3002\u7279\u8a31\u306f\u3001<a href=\"https:\/\/www.epo.org\/en\/legal\/epc\/2020\/a56.html\" rel=\"nofollow\">\u6b27\u5dde\u7279\u8a31\u6761\u7d04\uff08EPC\uff09\u7b2c56\u6761<\/a>\u306b\u7167\u3089\u3057\u3001\u5168\u90e8\u7121\u52b9\u3068\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<h2>\u8acb\u6c42\u9805\u306e\u89e3\u91c8\uff1a\u660e\u7d30\u66f8\u306e\u91cd\u307f<\/h2>\n<p>2024\u5e74\u5224\u6c7a\u306e\u7b2c\u4e00\u306e\u6301\u7d9a\u7684\u306a\u610f\u7fa9\u306f\u3001UPC\u306b\u304a\u3044\u3066\u306f\u3001\u660e\u7d30\u66f8\u304c\u66d6\u6627\u306a\u8acb\u6c42\u9805\u306b\u9650\u3063\u3066\u7528\u3044\u3089\u308c\u308b\u88dc\u5145\u7684\u306a\u624b\u6bb5\u3067\u306f\u306a\u304f\u3001\u5e38\u306b\u89e3\u91c8\u306b\u95a2\u4e0e\u3059\u308b\u3082\u306e\u3067\u3042\u308b\u3068\u3044\u3046\u70b9\u3067\u3059\u3002<em>Alexion<\/em>\u4e8b\u4ef6\u306e\u63a7\u8a34\u5be9\uff08UPC_CoA_402\/2024\u304a\u3088\u3073UPC_CoA_405\/2024\uff09\u306f\u3001\u6297\u4f53\u306b\u3064\u3044\u3066\u3053\u306e\u65b9\u91dd\u3092\u78ba\u8a8d\u3057\u307e\u3057\u305f\u3002\u3059\u306a\u308f\u3061\u3001\u53b3\u683c\u306a\u6587\u8a00\u89e3\u91c8\u3092\u884c\u3044\u3001\u4e0d\u5099\u306e\u3042\u308b\u8868\u73fe\u3092\u88c1\u5224\u6240\u304c\u6551\u6e08\u3059\u308b\u3053\u3068\u306f\u3057\u306a\u3044\u3001\u3068\u3044\u3046\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>EPO\u3068\u306e\u9694\u305f\u308a\u306f\u3001\u305d\u306e\u5f8c\u89e3\u6d88\u3055\u308c\u3066\u3044\u307e\u3059\u3002<a href=\"https:\/\/www.epo.org\/en\/boards-of-appeal\/decisions\/g240001ex1\" rel=\"nofollow\">2025\u5e746\u670818\u65e5\u306eG 1\/24\u6c7a\u5b9a<\/a>\u306b\u3088\u308a\u3001\u62e1\u5927\u5be9\u5224\u90e8\u306f\u3001\u8acb\u6c42\u9805\u306e\u89e3\u91c8\u306b\u3042\u305f\u3063\u3066\u306f\u660e\u7d30\u66f8\u304a\u3088\u3073\u56f3\u9762\u3092\u5e38\u306b\u53c2\u7167\u3057\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u70b9\u3067\u306f\u3001UPC\u306e\u5b9f\u52d9\u304c\u5148\u4f8b\u3068\u306a\u3063\u305f\u306e\u3067\u3059\u3002<\/p>\n<h2>2025\u5e7411\u670825\u65e5\uff1a\u63a7\u8a34\u5be9\u306b\u3088\u308b\u7834\u68c4<\/h2>\n<p>\u63a7\u8a34\uff08UPC_CoA_529\/2024\u304a\u3088\u3073UPC_CoA_528\/2024\uff09\u306b\u3064\u3044\u3066\u5224\u65ad\u3057\u305f\u63a7\u8a34\u88c1\u5224\u6240\u306f\u3001\u7121\u52b9\u5224\u65ad\u3092\u7834\u68c4\u3057\u3001\u7279\u8a31EP 3 666 797\u3092\u7dad\u6301\u3057\u307e\u3057\u305f\u3002<a href=\"https:\/\/www.unifiedpatentcourt.org\/en\/decisions-and-orders\" rel=\"nofollow\">UPC\u306e\u5224\u6c7a\u30fb\u547d\u4ee4\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9<\/a>\u3067\u95b2\u89a7\u3067\u304d\u308b\u3053\u306e\u5224\u6c7a\u306f\u3001\u81ea\u660e\u6027\u306b\u3064\u3044\u3066\u7dcf\u5408\u7684\u306a\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u63a1\u7528\u3057\u3066\u3044\u307e\u3059\u3002\u3059\u306a\u308f\u3061\u3001\u5f53\u696d\u8005\u306e\u52d5\u6a5f\u3065\u3051\u3068\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u306f\u3001\u9ad8\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u8840\u75c7\u306e\u6709\u52b9\u306a\u6cbb\u7642\u3092\u63d0\u4f9b\u3059\u308b\u3068\u3044\u3046\u5ba2\u89b3\u7684\u306a\u6280\u8853\u7684\u8ab2\u984c\u3068\u3001\u5148\u884c\u6280\u8853\u306b\u304a\u3051\u308b\u73fe\u5b9f\u7684\u306a\u51fa\u767a\u70b9\u3068\u3092\u57fa\u790e\u3068\u3057\u3066\u3001\u4e00\u4f53\u7684\u306b\u8a55\u4fa1\u3055\u308c\u308b\u3068\u3044\u3046\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>\u7d50\u8ad6\u3092\u5206\u3051\u305f\u306e\u306f\u7acb\u8a3c\u306e\u554f\u984c\u3067\u3057\u305f\u3002\u63a7\u8a34\u88c1\u5224\u6240\u306b\u3088\u308c\u3070\u3001\u5f53\u6642PCSK9\u306e\u4f5c\u7528\u7d4c\u8def\u3092\u3081\u3050\u3063\u3066\u79d1\u5b66\u7684\u306a\u4e0d\u78ba\u5b9f\u6027\u304c\u5b58\u5728\u3057\u3066\u3044\u305f\u3053\u3068\u306b\u7167\u3089\u3059\u3068\u3001\u5f53\u696d\u8005\u306f\u3001\u6297PCSK9\u6297\u4f53\u304c\u6cbb\u7642\u4e0a\u6709\u52b9\u3067\u3042\u308b\u3068\u5408\u7406\u7684\u306b\u4e88\u6e2c\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u63a7\u8a34\u88c1\u5224\u6240\u306f\u3055\u3089\u306b\u3001\u8acb\u6c42\u9805\u306e\u6587\u8a00\u306b\u5b8c\u5168\u306a\u52b9\u679c\u3092\u4e0e\u3048\u307e\u3057\u305f\u3002\u3059\u306a\u308f\u3061\u3001\u8acb\u6c42\u9805\u306b\u4fc2\u308b\u6297\u4f53\u306f\u3001\u5bfe\u8c61\u3068\u3059\u308b\u6cbb\u7642\u306b\u3064\u3044\u3066\u73fe\u5b9f\u306b\u6709\u52b9\u3067\u306a\u3051\u308c\u3070\u306a\u3089\u305a\u3001\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u304c\u4f55\u3089\u304b\u306e\u7a0b\u5ea6\u3067\u4f4e\u4e0b\u3059\u308b\u3060\u3051\u3067\u306f\u8db3\u308a\u306a\u3044\u3068\u3057\u305f\u306e\u3067\u3059\u3002<\/p>\n<p>\u3053\u306e\u7d50\u8ad6\u306f\u3001\u540c\u3058\u304f\u7279\u8a31\u3092\u5b58\u7d9a\u3055\u305b\u305fEPO\u306b\u304a\u3051\u308b\u7570\u8b70\u7533\u7acb\u3066\u624b\u7d9a\u306e\u5e30\u7d50\u3068\u3082\u4e00\u81f4\u3057\u307e\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001UPC\u306e\u4e21\u5be9\u7d1a\u306e\u9593\u306e\u76f8\u9055\u306f\u3001\u89e3\u91c8\u306e\u65b9\u6cd5\u306b\u3082\u3001\u8ab2\u984c\u89e3\u6c7a\u30a2\u30d7\u30ed\u30fc\u30c1\u306e\u4e0d\u63a1\u7528\u306b\u3082\u95a2\u308f\u308b\u3082\u306e\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u305d\u308c\u306f\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u306e\u6c34\u6e96\u3001\u3059\u306a\u308f\u3061\u512a\u5148\u65e5\u6642\u70b9\u306b\u304a\u3051\u308b\u6cbb\u7642\u4e0a\u306e\u6210\u529f\u306e<a href=\"\/ja\/lexique-propriete-intellectuelle\/plausibilite\/\">\u3082\u3063\u3068\u3082\u3089\u3057\u3055\uff08plausibility\uff09<\/a>\u306b\u95a2\u308f\u308b\u3082\u306e\u3060\u3063\u305f\u306e\u3067\u3059\u3002<\/p>\n<h2>\u6cbb\u7642\u7528\u6297\u4f53\uff1a\u4e00\u9023\u306e\u8a34\u8a1f\u3092\u7d4c\u305f\u6b27\u5dde\u306e\u57fa\u6e96<\/h2>\n<p>\u5927\u897f\u6d0b\u306e\u4e21\u5cb8\u306e\u5bfe\u6bd4\u306f\u3001\u4f9d\u7136\u3068\u3057\u3066\u793a\u5506\u306b\u5bcc\u3093\u3067\u3044\u307e\u3059\u3002\u7c73\u56fd\u3067\u306f\u3001Amgen\u306e\u6a5f\u80fd\u7684\u8acb\u6c42\u9805\u306f\u5b9f\u65bd\u53ef\u80fd\u8981\u4ef6\u306b\u3088\u3063\u3066\u5931\u52b9\u3057\u307e\u3057\u305f\u3002\u72ec\u5360\u306e\u7bc4\u56f2\u304c\u5e83\u3059\u304e\u3001\u958b\u793a\u306b\u3088\u308a\u518d\u73fe\u53ef\u80fd\u306a\u7bc4\u56f2\u3092\u8d85\u3048\u3066\u3044\u305f\u306e\u3067\u3059\u3002\u6b27\u5dde\u3067\u306f\u3001\u8b70\u8ad6\u306e\u7126\u70b9\u306f\u9032\u6b69\u6027\u3068\u305d\u306e\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u3078\u3068\u79fb\u308a\u307e\u3057\u305f\u3002\u6297\u4f53\u7279\u8a31\u3078\u306e\u9053\u306f\u72ed\u3044\u3082\u306e\u306e\u3001\u51fa\u9858\u306e\u6642\u70b9\u304b\u3089\u3001\u514b\u670d\u3055\u308c\u305f\u4e0d\u78ba\u5b9f\u6027\u3068\u5f97\u3089\u308c\u305f\u6cbb\u7642\u52b9\u679c\u3092\u8a18\u9332\u3057\u3066\u304a\u304f\u3053\u3068\u3092\u6761\u4ef6\u3068\u3057\u3066\u3001\u305d\u306e\u9053\u306f\u78ba\u304b\u306b\u5b58\u5728\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u4fb5\u5bb3\u306e\u9762\u3067\u306f\u3001\u30c7\u30e5\u30c3\u30bb\u30eb\u30c9\u30eb\u30d5\u5730\u65b9\u90e8\u304c2025\u5e745\u670813\u65e5\uff08UPC_CFI_505\/2024\uff09\u3001\u7b2c\u4e8c\u533b\u85ac\u7528\u9014\u306e\u8acb\u6c42\u9805\u306b\u3064\u3044\u3066\u3001\u56e0\u679c\u95a2\u4fc2\u3068\u88ab\u544a\u306e\u8a8d\u8b58\u3068\u3044\u3046\u4e8c\u3064\u306e\u8981\u7d20\u304b\u3089\u306a\u308b\u57fa\u6e96\u3092\u9069\u7528\u3057\u3001\u5168\u4f53\u50cf\u3092\u88dc\u5b8c\u3057\u307e\u3057\u305f\u3002\u6a29\u5229\u8005\u306b\u3068\u3063\u3066\u306e\u7dcf\u5408\u7684\u306a\u6559\u8a13\u306f\u660e\u3089\u304b\u3067\u3059\u3002\u6297\u4f53\u30d5\u30a1\u30df\u30ea\u30fc\u306e\u4fa1\u5024\u306f\u3001\u660e\u7d30\u66f8\u306e\u4f5c\u6210\u304b\u3089<a href=\"\/ja\/saisie-jub-preservation-des-preuves\/\">UPC\u306b\u304a\u3051\u308b\u8a3c\u62e0\u4fdd\u5168<\/a>\u306b\u81f3\u308b\u307e\u3067\u3001\u79d1\u5b66\u7684\u8cc7\u6599\u3068\u7acb\u8a3c\u8cc7\u6599\u306e\u8cea\u306b\u3088\u3063\u3066\u6c7a\u307e\u308a\u3001\u624b\u7d9a\u306e\u5404\u6bb5\u968e\u3067\u8986\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u306e\u3067\u3059\u3002<\/p>\n<h2>\u8981\u70b9<\/h2>\n<ul>\n<li>UPC\u306b\u304a\u3051\u308b\u521d\u306e\u7121\u52b9\u8a34\u8a1f\u306f2024\u5e747\u670816\u65e5\u306b\u8a8d\u5bb9\u3055\u308c\u307e\u3057\u305f\u3002\u30df\u30e5\u30f3\u30d8\u30f3\u4e2d\u592e\u90e8\u306f\u3001\u9032\u6b69\u6027\u306e\u6b20\u5982\u3092\u7406\u7531\u306b\u3001Amgen\u306e\u6297PCSK9\u7279\u8a31\u3092\u7121\u52b9\u3068\u3057\u307e\u3057\u305f\uff08UPC_CFI_1\/2023\uff09\u3002<\/li>\n<li>2025\u5e7411\u670825\u65e5\u3001\u63a7\u8a34\u88c1\u5224\u6240\u306f\u3053\u306e\u5224\u65ad\u3092\u7834\u68c4\u3057\uff08UPC_CoA_529\/2024\uff09\u3001\u5f53\u696d\u8005\u306b\u3068\u3063\u3066\u6cbb\u7642\u4e0a\u306e\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u304c\u306a\u304b\u3063\u305f\u3068\u3057\u3066\u3001\u7279\u8a31EP 3 666 797\u3092\u7dad\u6301\u3057\u307e\u3057\u305f\u3002<\/li>\n<li>UPC\u306f\u3001\u660e\u7d30\u66f8\u306b\u7167\u3089\u3057\u3066\u8acb\u6c42\u9805\u3092\u89e3\u91c8\u3057\u307e\u3059\u3002EPO\u30822025\u5e746\u670818\u65e5\u306eG 1\/24\u6c7a\u5b9a\u306b\u3088\u308a\u3053\u308c\u306b\u8db3\u4e26\u307f\u3092\u63c3\u3048\u307e\u3057\u305f\u3002<\/li>\n<li>\u63a7\u8a34\u88c1\u5224\u6240\u306f\u3001\u8ab2\u984c\u89e3\u6c7a\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u6a5f\u68b0\u7684\u306b\u9069\u7528\u3059\u308b\u3053\u3068\u306a\u304f\u3001\u81ea\u660e\u6027\u3092\u7dcf\u5408\u7684\u306b\u8a55\u4fa1\u3057\u307e\u3059\u3002\u52d5\u6a5f\u3065\u3051\u3068\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u306f\u4e00\u4f53\u7684\u306b\u691c\u8a0e\u3055\u308c\u307e\u3059\u3002<\/li>\n<li>\u65e2\u77e5\u306e\u6a19\u7684\u306b\u5bfe\u3059\u308b\u6297\u4f53\u306e\u958b\u767a\u306f\u3001\u5fc5\u305a\u3057\u3082\u30eb\u30fc\u30c6\u30a3\u30f3\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u8a18\u9332\u3055\u308c\u305f\u79d1\u5b66\u7684\u4e0d\u78ba\u5b9f\u6027\u306f\u3001\u9032\u6b69\u6027\u306e\u6839\u62e0\u3068\u306a\u308a\u5f97\u307e\u3059\u3002<\/li>\n<li>2023\u5e74\u306e\u7c73\u56fd\u5224\u6c7a\u3068\u306e\u6bd4\u8f03\u304b\u3089\u306f\u3001\u4e8c\u3064\u306e\u7570\u306a\u308b\u969c\u58c1\u304c\u898b\u3048\u3066\u304d\u307e\u3059\u3002\u7c73\u56fd\u3067\u306f\u5b9f\u65bd\u53ef\u80fd\u8981\u4ef6\u3001\u6b27\u5dde\u3067\u306f\u9032\u6b69\u6027\u3068\u3082\u3063\u3068\u3082\u3089\u3057\u3055\u3067\u3059\u3002<\/li>\n<\/ul>\n<h2>\u3088\u304f\u3042\u308b\u3054\u8cea\u554f<\/h2>\n<h3>Amgen\u306e\u7279\u8a31\u306e\u7121\u52b9\u5224\u65ad\u306f\u3001\u306a\u305c\u63a7\u8a34\u5be9\u3067\u7834\u68c4\u3055\u308c\u305f\u306e\u3067\u3059\u304b\u3002<\/h3>\n<p>\u63a7\u8a34\u88c1\u5224\u6240\u304c\u81ea\u660e\u6027\u3092\u7dcf\u5408\u7684\u306b\u8a55\u4fa1\u3057\u3001\u5f53\u6642\u306e\u79d1\u5b66\u7684\u4e0d\u78ba\u5b9f\u6027\u306b\u7167\u3089\u305b\u3070\u3001\u5f53\u696d\u8005\u306f\u6297PCSK9\u6297\u4f53\u306e\u6cbb\u7642\u52b9\u679c\u3092\u5408\u7406\u7684\u306b\u4e88\u6e2c\u3059\u308b\u3053\u3068\u306f\u3067\u304d\u306a\u304b\u3063\u305f\u3068\u5224\u65ad\u3057\u305f\u305f\u3081\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u9032\u6b69\u6027\u304c\u8a8d\u3081\u3089\u308c\u307e\u3057\u305f\u3002<\/p>\n<h3>UPC\u306f\u3001EPO\u306e\u8ab2\u984c\u89e3\u6c7a\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u9069\u7528\u3057\u3066\u3044\u308b\u306e\u3067\u3059\u304b\u3002<\/h3>\n<p>\u3044\u3044\u3048\u3001\u6a5f\u68b0\u7684\u306b\u306f\u9069\u7528\u3057\u3066\u3044\u307e\u305b\u3093\u3002UPC\u306f\u3001\u5148\u884c\u6280\u8853\u306b\u304a\u3051\u308b\u73fe\u5b9f\u7684\u306a\u51fa\u767a\u70b9\u304b\u3089\u51fa\u767a\u3057\u3001\u52d5\u6a5f\u3065\u3051\u3068\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u3092\u4e00\u4f53\u7684\u306b\u8a55\u4fa1\u3057\u307e\u3059\u3002\u3053\u306e\u65b9\u6cd5\u306f\u30012025\u5e7411\u670825\u65e5\u306e\u5224\u6c7a\u306b\u304a\u3044\u3066\u63a7\u8a34\u88c1\u5224\u6240\u306b\u3088\u308a\u78ba\u8a8d\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<h3>\u6297\u4f53\u7279\u8a31\u306e\u660e\u7d30\u66f8\u4f5c\u6210\u306b\u306f\u3069\u306e\u3088\u3046\u306a\u5f71\u97ff\u304c\u3042\u308a\u307e\u3059\u304b\u3002<\/h3>\n<p>\u51fa\u9858\u306e\u6642\u70b9\u304b\u3089\u3001\u514b\u670d\u3057\u305f\u6280\u8853\u7684\u4e0d\u78ba\u5b9f\u6027\u3068\u3001\u8acb\u6c42\u9805\u306b\u4fc2\u308b\u6297\u4f53\u306e\u73fe\u5b9f\u306e\u6cbb\u7642\u52b9\u679c\u3092\u8a18\u9332\u3057\u3066\u304a\u304f\u3053\u3068\u3001\u305d\u3057\u3066\u8acb\u6c42\u9805\u3068\u660e\u7d30\u66f8\u3092\u53b3\u683c\u306b\u6574\u5408\u3055\u305b\u308b\u3053\u3068\u3067\u3059\u3002UPC\u3082EPO\u3082\u3001\u73fe\u5728\u3067\u306f\u660e\u7d30\u66f8\u306b\u7167\u3089\u3057\u3066\u8acb\u6c42\u9805\u3092\u89e3\u91c8\u3057\u3066\u3044\u308b\u305f\u3081\u3067\u3059\u3002<\/p>\n<h3>UPC\u306b\u3088\u308b\u7121\u52b9\u5224\u65ad\u306f\u3001\u6b27\u5dde\u5168\u4f53\u306b\u52b9\u529b\u3092\u6709\u3059\u308b\u306e\u3067\u3059\u304b\u3002<\/h3>\n<p>\u7279\u8a31\u304c\u52b9\u529b\u3092\u6709\u3059\u308b\u3059\u3079\u3066\u306e\u7de0\u7d04\u52a0\u76df\u56fd\u306b\u304a\u3044\u3066\u52b9\u529b\u3092\u6709\u3057\u307e\u3059\u3002\u3053\u306e\u305f\u3081\u3001\u4e00\u5143\u7684\u306a\u7121\u52b9\u8a34\u8a1f\u306f\u5f37\u529b\u306a\u624b\u6bb5\u3068\u306a\u308a\u307e\u3059\u304c\u3001\u672c\u4ef6\u304c\u793a\u3059\u3068\u304a\u308a\u3001\u305d\u306e\u5e30\u7d50\u306f\u63a7\u8a34\u5be9\u3067\u8986\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>Dhenne Avocats\u306f\u3001<a href=\"\/ja\/contentieux-des-brevets\/action-en-nullite-brevet\/\">\u7121\u52b9\u8a34\u8a1f<\/a>\u3068\u6709\u52b9\u6027\u306e\u9632\u5fa1\u3092\u3001<a href=\"\/ja\/domaines-d-expertise\/jub\/\">\u7d71\u4e00\u7279\u8a31\u88c1\u5224\u6240<\/a>\u304a\u3088\u3073\u30d5\u30e9\u30f3\u30b9\u306e\u88c1\u5224\u6240\u306b\u304a\u3044\u3066\u3001\u7279\u306b\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u304a\u3088\u3073\u6cbb\u7642\u7528\u6297\u4f53\u306e\u5206\u91ce\u3067\u624b\u304c\u3051\u3066\u3044\u307e\u3059\u3002<a href=\"\/ja\/contact\/\">\u3054\u76f8\u8ac7\u306f\u3053\u3061\u3089<\/a>\u3002<\/p>\n<p><em>\u672c\u7a3f\u306f\u3001Matthieu Dhenne\u304c2024\u5e747\u670824\u65e5\u306bKluwer Patent Blog\u3067\u6700\u521d\u306b\u516c\u8868\u3057\u305f\u5206\u6790\u3092\u3001\u72ec\u81ea\u306b\u7ffb\u6848\u3057\u3001\u5927\u5e45\u306b\u66f4\u65b0\u3057\u305f\u3082\u306e\u3067\u3059\uff1a<a href=\"https:\/\/legalblogs.wolterskluwer.com\/patent-blog\/sanofi-vs-amgen-successful-first-upc-revocation-action-and-strict-assessment-of-therapeutic-antibodies-patentability\/\" rel=\"nofollow\">Sanofi vs. Amgen\uff1aUPC\u306b\u304a\u3051\u308b\u521d\u306e\u7121\u52b9\u8a34\u8a1f\u306e\u6210\u529f\u3068\u6cbb\u7642\u7528\u6297\u4f53\u306e\u7279\u8a31\u6027\u306e\u53b3\u683c\u306a\u8a55\u4fa1<\/a>\u3002<\/em><\/p>\n<p><!-- DA-ACF-JA --><\/p>\n<h2>\u4e8b\u6848\u306e\u6982\u8981<\/h2>\n<p>\u672c\u4ef6\u3067\u306f\u3001PCSK9\u6297\u4f53\u306b\u95a2\u3059\u308bAmgen\u306e\u7279\u8a31\u306e\u4e00\u3064\u3067\u3042\u308b\u7279\u8a31<a href=\"https:\/\/register.epo.org\/application?number=EP19207796\">EP 3,666,797<\/a>\u306b\u5bfe\u3057\u3066\u7121\u52b9\u8a34\u8a1f\uff08revocation action\uff09\u304c\u63d0\u8d77\u3055\u308c\u307e\u3057\u305f\u3002\u3053\u306e\u7279\u8a31\u306e\u8acb\u6c42\u98051\u306f\u3001\u9ad8\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u8840\u75c7\u307e\u305f\u306f\u52d5\u8108\u786c\u5316\u6027\u75be\u60a3\u306e\u6cbb\u7642\u307e\u305f\u306f\u4e88\u9632\u306b\u7528\u3044\u3089\u308c\u308b\u6297\u4f53\u3067\u3042\u3063\u3066\u3001\u5f53\u8a72\u6297\u4f53\u304c\u300c\u30a2\u30df\u30ce\u9178\u914d\u5217SEQ ID NO: 1\u306ePCSK9\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u89e6\u5a92\u30c9\u30e1\u30a4\u30f3\u306b\u7d50\u5408\u3057\u3001PCSK9\u306eLDLR\u3078\u306e\u7d50\u5408\u3092\u963b\u6b62\u307e\u305f\u306f\u4f4e\u6e1b\u3059\u308b\u300d\u3082\u306e\u306b\u95a2\u3059\u308b\u3082\u306e\u3067\u3057\u305f\u3002Sanofi\u306e3\u793e\u306f\u3001UPCA\uff08\u7d71\u4e00\u7279\u8a31\u88c1\u5224\u6240\u5354\u5b9a\uff09\u306e\u767a\u52b9\u65e5\u3067\u3042\u308b2023\u5e746\u67081\u65e5\u306b\u3001\u7d71\u4e00\u7279\u8a31\u88c1\u5224\u6240\uff08UPC\uff09\u4e2d\u592e\u90e8\u306e\u30df\u30e5\u30f3\u30d8\u30f3\u90e8\u9580\u306b\u672c\u8a34\u3068\u3057\u3066\u7121\u52b9\u8a34\u8a1f\u3092\u63d0\u8d77\u3057\u307e\u3057\u305f\u3002\u4ed6\u65b9\u3001\u540c\u65e5\u306e\u6570\u5206\u5f8c\u3001Amgen\u306f\u30df\u30e5\u30f3\u30d8\u30f3\u5730\u65b9\u90e8\u306b\u304a\u3044\u3066\u3001\u3053\u308c\u30893\u793e\u304a\u3088\u3073Regeneron\u3092\u76f8\u624b\u65b9\u3068\u3057\u3066\u4fb5\u5bb3\u8a34\u8a1f\u3092\u63d0\u8d77\u3057\u307e\u3057\u305f\u3002\u305d\u306e\u5f8c\u3001Regeneron\u306f\u7121\u52b9\u306e\u53cd\u8a34\u3092\u63d0\u8d77\u3057\u307e\u3057\u305f\u304c\u3001Sanofi\u306e\u5404\u793e\u306f\u3053\u308c\u3092\u884c\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u4e2d\u592e\u90e8\u3068\u5730\u65b9\u90e8\u3068\u306b\u304a\u3044\u3066\u985e\u4f3c\u306e\u7121\u52b9\u8a34\u8a1f\u304c\u4e26\u884c\u3057\u3066\u4fc2\u5c5e\u3059\u308b\u3053\u3068\u3068\u306a\u3063\u305f\u305f\u3081\u3001\u5168\u5f53\u4e8b\u8005\u306f\u3001\u7121\u52b9\u306e\u53cd\u8a34\u3092\u4e2d\u592e\u90e8\u306b\u79fb\u9001\u3059\u3079\u304d\u3053\u3068\u306b\u5408\u610f\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u3089\u306e\u8a34\u8a1f\u306f\u3001\u63a7\u3048\u3081\u306b\u8a00\u3063\u3066\u3082\u8907\u96d1\u306a\u80cc\u666f\u306e\u3082\u3068\u306b\u3042\u308a\u307e\u3059\u3002Amgen\u3001Sanofi\u304a\u3088\u3073Regeneron\u306f\u30012014\u5e74\u4ee5\u6765\u3001Amgen\u306ePCSK9\u6297\u4f53\u306b\u95a2\u3059\u308b\u7279\u8a31\u3092\u3081\u3050\u3063\u3066\u4e89\u3063\u3066\u304a\u308a\u3001\u3053\u308c\u3089\u306e\u7279\u8a31\u306f\u3001Amgen\u306eRepatha\u3068\u3001Sanofi\u304a\u3088\u3073Regeneron\u304c\u8ca9\u58f2\u3059\u308bPraluent\u306e\u53cc\u65b9\u3092\u5bfe\u8c61\u3068\u3059\u308b\u3068\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u5f53\u521d\u3001\u7d1b\u4e89\u306f\u6b27\u5dde\u5404\u56fd\u306e\u56fd\u5185\u88c1\u5224\u6240\u306b\u4fc2\u5c5e\u3057\u3001\u305d\u306e\u5f8cUPC\u306b\u6301\u3061\u8fbc\u307e\u308c\u307e\u3057\u305f\u3002EP\u2019797\u306b\u5bfe\u5fdc\u3059\u308b\u7c73\u56fd\u7279\u8a31\u306b\u95a2\u3059\u308b\u4e8b\u4ef6\u306f\u3001\u7c73\u56fd\u9023\u90a6\u6700\u9ad8\u88c1\u5224\u6240\u306b\u3082\u4fc2\u5c5e\u3057\u307e\u3057\u305f\u3002<\/p>\n<h2>\u672c\u5224\u6c7a\u306e\u7b2c\u4e00\u306e\u610f\u7fa9<\/h2>\n<p>UPC\u306e\u672c\u5224\u6c7a\u306e\u4e3b\u305f\u308b\u610f\u7fa9\u306f\u3001\u6cbb\u7642\u7528\u6297\u4f53\u306e\u7279\u8a31\u6027\u306b\u95a2\u3059\u308b\u5224\u793a\u306b\u3042\u308a\u307e\u3059\u3002\u88c1\u5224\u6240\u306f\u307e\u305a\u3001\u8acb\u6c42\u98051\u306e\u89e3\u91c8\u3001\u3057\u305f\u304c\u3063\u3066\u305d\u306e\u89e3\u91c8\u65b9\u6cd5\u306b\u53d6\u308a\u7d44\u307f\u307e\u3057\u305f\u3002\u7b2c\u4e00\u306b\u3001\u88c1\u5224\u6240\u306f\u3001\u8acb\u6c42\u9805\u3092\u89e3\u91c8\u3059\u308b\u5f53\u696d\u8005\u306f\u3001\u660e\u7d30\u66f8\u304a\u3088\u3073\u56f3\u9762\u3092\u7528\u3044\u3066\u3001\u4f7f\u7528\u3055\u308c\u3066\u3044\u308b\u7528\u8a9e\u306e\u6280\u8853\u7684\u610f\u5473\u3092\u78ba\u5b9a\u3059\u308b\u3068\u5224\u793a\u3057\u3066\u3044\u307e\u3059\u3002\u6b21\u306b\u3001\u88c1\u5224\u6240\u306f\u3001\u300cPCSK9\u306e\u89e6\u5a92\u30c9\u30e1\u30a4\u30f3\u306b\u7d50\u5408\u3059\u308b\u300d\u3068\u3044\u3046\u8acb\u6c42\u9805\u306e\u6a5f\u80fd\u7684\u7279\u5fb4\u3092\u691c\u8a0e\u3057\u307e\u3057\u305f\u3002\u3053\u3053\u3067\u554f\u984c\u3068\u306a\u308b\u306e\u306f\u3001\u8acb\u6c42\u9805\u306e\u6a5f\u80fd\u7684\u9650\u5b9a\u3092\u3069\u306e\u3088\u3046\u306b\u7406\u89e3\u3059\u308b\u304b\u3067\u3059\u3002\u88c1\u5224\u6240\u306f\u3001\u5f53\u696d\u8005\u306b\u3068\u3063\u3066\u3001\u6297\u4f53\u306e\u7d50\u5408\u306b\u306f\u4e00\u3064\u306e\u6a5f\u80fd\u3001\u3059\u306a\u308f\u3061PCSK9\u306eLDLR\u3078\u306e\u7d50\u5408\u3092\u963b\u6b62\u307e\u305f\u306f\u4f4e\u6e1b\u3059\u308b\u3068\u3044\u3046\u6a5f\u80fd\u304c\u3042\u308b\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002\u3057\u304b\u3057\u3001\u6280\u8853\u7684\u6a5f\u80fd\u304c\u5b9f\u73fe\u3055\u308c\u308b\u305f\u3081\u306b\u306f\u7d50\u5408\u304c\u5c02\u3089\u3001\u307e\u305f\u306f\u4e3b\u3068\u3057\u3066\u89e6\u5a92\u30c9\u30e1\u30a4\u30f3\u306b\u304a\u3044\u3066\u751f\u3058\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u3068\u306e\u793a\u5506\u304c\u8acb\u6c42\u9805\u306b\u3082\u660e\u7d30\u66f8\u306b\u3082\u4e00\u5207\u306a\u3044\u4ee5\u4e0a\u3001\u5f53\u696d\u8005\u304c\u305d\u306e\u3088\u3046\u306b\u7406\u89e3\u3059\u308b\u3053\u3068\u306f\u306a\u304b\u3063\u305f\u3067\u3042\u308d\u3046\u3001\u3068\u3044\u3046\u7d50\u8ad6\u306b\u306a\u308a\u307e\u3059\u3002\u3055\u3089\u306b\u88c1\u5224\u6240\u306f\u3001\u3082\u3046\u4e00\u3064\u306e\u6a5f\u80fd\u7684\u9650\u5b9a\u3001\u3059\u306a\u308f\u3061\u6297\u4f53\u306e\u6cbb\u7642\u52b9\u679c\uff08\u3064\u307e\u308a\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u306e\u4f4e\u4e0b\uff09\u306b\u3088\u308a\u3001\u8acb\u6c42\u9805\u306f\uff08\u305f\u3068\u3048\u300c\u975e\u5e38\u306b\u308f\u305a\u304b\u300d\u3067\u3042\u3063\u3066\u3082\uff09\u6cbb\u7642\u52b9\u679c\u3092\u6709\u3059\u308b\u6297\u4f53\u306e\u307f\u3092\u5bfe\u8c61\u3068\u3059\u308b\u3053\u3068\u306b\u306a\u308b\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002\u7d50\u5c40\u306e\u3068\u3053\u308d\u3001\u8acb\u6c42\u9805\u306e\u6a5f\u80fd\u7684\u6587\u8a00\u306f\u3001\u300c\u89e6\u5a92\u30c9\u30e1\u30a4\u30f3\u306b\u7d50\u5408\u3057\u5f97\u308b\u3059\u3079\u3066\u306e\u6297\u4f53\u300d\u3092\u5bfe\u8c61\u3068\u3059\u308b\u3082\u306e\u3068\u89e3\u91c8\u3055\u308c\u308b\u3079\u304d\u3067\u306f\u306a\u3044\u3068\u3055\u308c\u307e\u3057\u305f\u3002\u3053\u306e\u3088\u3046\u306a\u89e3\u91c8\u304b\u3089\u306f\u3001\u88c1\u5224\u6240\u304c\u3001\u6b27\u5dde\u7279\u8a31\u5e81\uff08EPO\uff09\u306e\u5be9\u5224\u90e8\u304c\u4e00\u822c\u306b\u8a8d\u3081\u308b\u3088\u308a\u3082\u5927\u304d\u306a\u91cd\u307f\u3092\u660e\u7d30\u66f8\u306b\u4e0e\u3048\u3088\u3046\u3068\u3057\u3066\u3044\u308b\u3053\u3068\u304c\u3046\u304b\u304c\u308f\u308c\u307e\u3059\uff08\u305f\u3068\u3048\u3070<a href=\"https:\/\/www.epo.org\/en\/boards-of-appeal\/decisions\/t200169eu1\">T 169\/20<\/a>\u306f\u3001\u300c\u8acb\u6c42\u9805\u3092\u89e3\u91c8\u3059\u308b\u305f\u3081\u306e\u660e\u7d30\u66f8\u306b\u3088\u308b\u88cf\u3065\u3051\u306f\u3001\u767a\u660e\u306e\u4e3b\u984c\u304a\u3088\u3073\uff0f\u307e\u305f\u306f\u305d\u306e\u6280\u8853\u7684\u6587\u8108\u3092\u660e\u78ba\u306b\u3059\u308b\u5fc5\u8981\u304c\u3042\u308b\u4f8b\u5916\u7684\u306a\u5834\u5408\u306b\u306e\u307f\u7528\u3044\u3089\u308c\u308b\u3079\u304d\u3067\u3042\u308a\u3001\u660e\u7d30\u66f8\u306b\u304a\u3051\u308b\u767a\u660e\u304c\u8acb\u6c42\u3055\u308c\u3066\u3044\u308b\u767a\u660e\u3068\u4e00\u81f4\u3059\u308b\u5834\u5408\u306b\u306e\u307f\u9069\u7528\u3055\u308c\u5f97\u308b\u300d\u3068\u3057\u3066\u3044\u307e\u3059\uff09\u3002<\/p>\n<h2>\u672c\u5224\u6c7a\u306e\u7b2c\u4e8c\u306e\u610f\u7fa9<\/h2>\n<p>\u6b21\u306b\u3001\u88c1\u5224\u6240\u306f\u9032\u6b69\u6027\u306e\u8981\u4ef6\uff08<a href=\"https:\/\/www.epo.org\/en\/legal\/epc\/2020\/a56.html\">\u6b27\u5dde\u7279\u8a31\u6761\u7d04\u7b2c56\u6761<\/a>\uff09\u306b\u95a2\u3059\u308b\u5206\u6790\u3092\u5c55\u958b\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u3053\u3067\u6ce8\u76ee\u3059\u3079\u304d\u306f\u3001\u88c1\u5224\u6240\u304c\u3001EPO\u3067\u4f1d\u7d71\u7684\u306b\u7528\u3044\u3089\u308c\u3066\u3044\u308b\u8ab2\u984c\u89e3\u6c7a\u30a2\u30d7\u30ed\u30fc\u30c1\u306b\u5f93\u308f\u306a\u3044\u3053\u3068\u3092\u9078\u629e\u3057\u3001\u6700\u3082\u8fd1\u3044\u5148\u884c\u6280\u8853\u3001\u3059\u306a\u308f\u3061\u6700\u3082\u6709\u671b\u306a\u5148\u884c\u6280\u8853\uff08<a href=\"https:\/\/www.epo.org\/en\/legal\/guidelines-epc\/2024\/g_vii_5_1.html\">EPO\u5be9\u67fb\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3G-VII-5.1<\/a>\uff09\u304b\u3089\u51fa\u767a\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u73fe\u5b9f\u7684\u306a\u51fa\u767a\u70b9\u304b\u3089\u51fa\u767a\u3059\u308b\u306b\u3068\u3069\u3081\u305f\u70b9\u3067\u3059\u3002\u4e2d\u592e\u90e8\u306f\u3001\u672c\u4ef6\u306b\u304a\u3044\u3066\u3001\u5148\u884c\u6280\u8853\u306b\u306f\u3001PCSK9\u3068LDLR\u3068\u306e\u7d50\u5408\u3092\u963b\u6b62\u3057\u5f97\u308b\u6297\u4f53\u306e\u958b\u767a\u306b\u5411\u3051\u305f\u660e\u793a\u7684\u306a\u793a\u5506\u304c\u3042\u3063\u305f\u3068\u5224\u65ad\u3057\u307e\u3057\u305f\u3002\u5f53\u696d\u8005\u3067\u3042\u308c\u3070\u3001\u5148\u884c\u6280\u8853\u304b\u3089\u3001\u3053\u306e\u7d50\u5408\u306e\u963b\u6b62\u304c\u9ad8\u30b3\u30ec\u30b9\u30c6\u30ed\u30fc\u30eb\u8840\u75c7\u306e\u6cbb\u7642\u306e\u305f\u3081\u306b\u63a2\u6c42\u3055\u308c\u5f97\u308b\u3053\u3068\u3092\u7406\u89e3\u3057\u305f\u3067\u3042\u308d\u3046\u304b\u3089\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u3053\u306e\u793a\u5506\u3092\u8003\u616e\u3059\u308c\u3070\u3001\u5f53\u696d\u8005\u306f\u3001\u6297\u4f53\u306e\u4f5c\u88fd\u304a\u3088\u3073\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u65b9\u6cd5\u306e\u78ba\u7acb\u306b\u76f8\u5f53\u306a\u6642\u9593\u3068\u8cc7\u6e90\u3092\u8981\u3057\u5f97\u308b\u3053\u3068\u3092\u8a8d\u8b58\u3057\u305f\u3068\u3057\u3066\u3082\u3001\u9032\u6b69\u6027\u3092\u767a\u63ee\u3059\u308b\u3053\u3068\u306a\u304f\u3001\u8acb\u6c42\u9805\u306b\u5b9a\u7fa9\u3055\u308c\u305f\u6297\u4f53\u3092\u5f97\u308b\u3053\u3068\u306b\u6210\u529f\u3059\u308b\u5408\u7406\u7684\u306a\u898b\u8fbc\u307f\u3092\u6709\u3057\u3066\u3044\u305f\u3067\u3042\u308d\u3046\u3068\u3055\u308c\u307e\u3057\u305f\u3002\u3053\u3046\u3057\u3066\u88c1\u5224\u6240\u306f\u3001\u5f53\u696d\u8005\u306b\u306fPCSK9\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u7528\u6297\u4f53\u3092\u958b\u767a\u3059\u308b\u52d5\u6a5f\u304c\u3042\u308a\u3001\u300c\u904e\u5ea6\u306e\u8ca0\u62c5\u300d\uff08\u5fc5\u8981\u306a\u6642\u9593\u3068\u8cc7\u6e90\u3092\u6307\u3059\u3082\u306e\uff09\u306a\u304f\u3001\u5408\u7406\u7684\u306a\u6210\u529f\u306e\u898b\u8fbc\u307f\u3092\u3082\u3063\u3066\u8acb\u6c42\u9805\u306b\u4fc2\u308b\u6297\u4f53\u306b\u5230\u9054\u3057\u305f\u3067\u3042\u308d\u3046\u3068\u5224\u65ad\u3057\u3066\u3001\u672c\u7279\u8a31\u3092\u305d\u306e\u5168\u4f53\u306b\u3064\u3044\u3066\uff08\u3059\u306a\u308f\u3061\u3001\u3053\u3053\u3067\u306fUPC\u306e\u3059\u3079\u3066\u306e\u7de0\u7d04\u56fd\u306b\u3064\u3044\u3066\uff09\u7121\u52b9\u3068\u3057\u307e\u3057\u305f\u3002<\/p>\n<h2>\u7d50\u8ad6<\/h2>\n<p>\u4e0a\u8ff0\u306e\u3068\u304a\u308a\u3001\u30df\u30e5\u30f3\u30d8\u30f3\u306e\u4e2d\u592e\u90e8\u306f\u3001\u8acb\u6c42\u9805\u306e\u89e3\u91c8\u304a\u3088\u3073\u9032\u6b69\u6027\u306e\u8a55\u4fa1\u306b\u3064\u3044\u3066\u3001EPO\u306e\u7acb\u5834\u304b\u3089\u308f\u305a\u304b\u306b\u96e2\u308c\u3066\u3044\u307e\u3059\u3002\u305d\u308c\u3067\u3082\u306a\u304a\u3001\u6297\u4f53\u306e\u7279\u8a31\u6027\u306b\u95a2\u3059\u308b\u7d50\u8ad6\u306fEPO\u306e\u305d\u308c\u306b\u8fd1\u304f\u3001\u3057\u305f\u304c\u3063\u3066\u7c73\u56fd\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u3068\u3082\u7570\u306a\u308b\u3082\u306e\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u88c1\u5224\u6240\u306e\u7acb\u5834\u306f\u3001\u300c\u65e2\u77e5\u306e\u6297\u539f\u306b\u7d50\u5408\u3059\u308b\u65b0\u898f\u306a\u6297\u4f53\u3092\u5b9a\u7fa9\u3059\u308b\u8acb\u6c42\u9805\u306e\u4e3b\u984c\u306f\u3001\u8acb\u6c42\u9805\u306b\u304a\u3044\u3066\u9a5a\u304f\u3079\u304d\u6280\u8853\u7684\u52b9\u679c\u304c\u793a\u3055\u308c\u3066\u3044\u308b\u5834\u5408\u3001\u307e\u305f\u306f\u5fc5\u8981\u306a\u7279\u6027\u3092\u6709\u3059\u308b\u6297\u4f53\u3092\u5f97\u308b\u3053\u3068\u306b\u3064\u3044\u3066\u5408\u7406\u7684\u306a\u671f\u5f85\u304c\u306a\u304b\u3063\u305f\u5834\u5408\u3092\u9664\u304d\u3001\u9032\u6b69\u6027\u3092\u6709\u3057\u306a\u3044\u300d\u3068\u3059\u308bEPO\u306e\u7acb\u5834\uff08<a href=\"https:\/\/www.epo.org\/en\/legal\/guidelines-epc\/2023\/g_ii_5_6_2.html\">EPO\u5be9\u67fb\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3G-II-5.6.2<\/a>\uff09\u306b\u8fd1\u3044\u3082\u306e\u3067\u3059\u3002\u3053\u306e\u3088\u3046\u306b\u3001\u30c9\u30a4\u30c4\u306e\u5730\u65b9\u90e8\u306b\u3088\u308c\u3070\u3001\u7279\u6bb5\u306e\u56f0\u96e3\u304c\u306a\u3044\u9650\u308a\u3001\u65e2\u77e5\u306e\u6a19\u7684\u306b\u5bfe\u3059\u308b\u6297\u4f53\u306e\u958b\u767a\u306f\u30eb\u30fc\u30c1\u30f3\u4f5c\u696d\u3067\u3042\u308a\u3001\u3057\u305f\u304c\u3063\u3066\u9032\u6b69\u6027\u306f\u306a\u3044\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002\u3053\u308c\u306f\u3001\u5b9f\u65bd\u53ef\u80fd\u8981\u4ef6\uff08enablement\uff09\u306b\u57fa\u3065\u304f\u7c73\u56fd\u3067\u306e\u7121\u52b9\u3068\u306f\u5bfe\u7167\u7684\u3067\u3059\u3002\u7c73\u56fd\u3067\u306f\u3001\u9023\u90a6\u6700\u9ad8\u88c1\u5224\u6240\u306b\u3088\u308c\u3070\u3001\u660e\u7d30\u66f8\u304b\u3089\u51fa\u767a\u3057\u305f\u3068\u3057\u3066\u3082\u3001\u5f53\u696d\u8005\u306fAmgen\u306e\u7279\u8a31\u304c\u5bfe\u8c61\u3068\u3059\u308b\u6570\u767e\u4e07\u306e\u6297\u4f53\u306b\u5230\u9054\u3059\u308b\u305f\u3081\u306b\u767a\u660e\u7684\u306a\u52aa\u529b\u3092\u3057\u306a\u3051\u308c\u3070\u306a\u3089\u306a\u3044\u3053\u3068\u304b\u3089\u3001\u5b9f\u65bd\u53ef\u80fd\u8981\u4ef6\u304c\u6e80\u305f\u3055\u308c\u3066\u3044\u306a\u3044\u3068\u5224\u65ad\u3055\u308c\u307e\u3057\u305f\uff0821-757 Amgen Inc. v. Sanofi (05\/18\/23)\uff09\u3002\u7d50\u5c40\u306e\u3068\u3053\u308d\u3001UPC\u306f\u3001\u6b27\u5dde\u306b\u304a\u3044\u3066\u3001\u7c73\u56fd\u3088\u308a\u3082\u306f\u308b\u304b\u306b\u9ad8\u3044\u6297\u4f53\u306e\u7279\u8a31\u6027\u306e\u57fa\u6e96\u3092\u8a2d\u5b9a\u3057\u305f\u3068\u3044\u3048\u307e\u3059\u3002<\/p>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Premi\u00e8re action en r\u00e9vocation aboutie devant la JUB le 16 juillet 2024, puis infirmation par la Cour d&rsquo;appel le 25 novembre 2025 : la saga PCSK9 fixe le r\u00e9f\u00e9rentiel europ\u00e9en de l&rsquo;activit\u00e9 inventive des anticorps th\u00e9rapeutiques.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[29,7,28],"tags":[],"class_list":["post-10242","post","type-post","status-publish","format-standard","hentry","category-brevetabilite","category-jub","category-pharmaceutique"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Action en nullit\u00e9 JUB : Sanofi c. Amgen et les anticorps<\/title>\n<meta name=\"description\" content=\"Premi\u00e8re action en nullit\u00e9 devant la JUB : annulation du 16 juillet 2024 puis infirmation en appel le 25 novembre 2025. Activit\u00e9 inventive des anticorps.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.dhenne-avocats.fr\/ja\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Action en nullit\u00e9 JUB : Sanofi c. Amgen et les anticorps\" \/>\n<meta property=\"og:description\" content=\"Premi\u00e8re action en nullit\u00e9 devant la JUB : annulation du 16 juillet 2024 puis infirmation en appel le 25 novembre 2025. Activit\u00e9 inventive des anticorps.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.dhenne-avocats.fr\/ja\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Dhenne Avocats\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-30T10:37:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-23T16:32:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/og-dhenne-avocats-fr.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Matthieu Dhenne\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@matthieu_dhenne\" \/>\n<meta name=\"twitter:site\" content=\"@DhenneAvocats\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Matthieu Dhenne\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"13\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\"},\"author\":{\"name\":\"Matthieu Dhenne\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/person\\\/cebb642899b1d41301d41a0187fa329c\"},\"headline\":\"Sanofi c. Amgen : la premi\u00e8re action en nullit\u00e9 de la JUB et la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques, de l&rsquo;annulation \u00e0 l&rsquo;infirmation\",\"datePublished\":\"2024-07-30T10:37:53+00:00\",\"dateModified\":\"2026-10-23T16:32:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\"},\"wordCount\":3209,\"publisher\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\"},\"articleSection\":[\"Brevetabilit\u00e9\",\"JUB\",\"Pharmaceutique\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\",\"name\":\"Action en nullit\u00e9 JUB : Sanofi c. Amgen et les anticorps\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#website\"},\"datePublished\":\"2024-07-30T10:37:53+00:00\",\"dateModified\":\"2026-10-23T16:32:01+00:00\",\"description\":\"Premi\u00e8re action en nullit\u00e9 devant la JUB : annulation du 16 juillet 2024 puis infirmation en appel le 25 novembre 2025. Activit\u00e9 inventive des anticorps.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi c. Amgen : la premi\u00e8re action en nullit\u00e9 de la JUB et la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques, de l&rsquo;annulation \u00e0 l&rsquo;infirmation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\",\"name\":\"Dhenne Avocats\",\"description\":\"Cabinet d&#039;avocats en droit des brevets\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#organization\",\"name\":\"Dhenne Avocats\",\"alternateName\":\"dhenne avocats\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"contentUrl\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png\",\"width\":512,\"height\":512,\"caption\":\"Dhenne Avocats\"},\"image\":{\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DhenneAvocats\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dhenne-avocat\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.dhenne-avocats.fr\\\/#\\\/schema\\\/person\\\/cebb642899b1d41301d41a0187fa329c\",\"name\":\"Matthieu Dhenne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g\",\"caption\":\"Matthieu Dhenne\"},\"description\":\"Avocat au barreau de Paris depuis 2014, docteur en droit, fondateur de Dhenne Avocats, cabinet d\u00e9di\u00e9 au contentieux des brevets d\u2019invention. Repr\u00e9sentant devant la Juridiction unifi\u00e9e du brevet. Enseigne le droit de la propri\u00e9t\u00e9 industrielle \u00e0 l\u2019Universit\u00e9 Panth\u00e9on-Assas et assure la correspondance fran\u00e7aise du Kluwer Patent Blog.\",\"sameAs\":[\"https:\\\/\\\/www.dhenne-avocats.fr\\\/equipe-nos-avocats-brevets\\\/matthieu-dhenne\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/matthieudhenne\\\/\",\"https:\\\/\\\/x.com\\\/matthieu_dhenne\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UPC\u306e\u7121\u52b9\u8a34\u8a1f\uff1aSanofi c. Amgen\u3068\u6297\u4f53\u7279\u8a31","description":"UPC\u306b\u304a\u3051\u308b\u521d\u306e\u7121\u52b9\u8a34\u8a1f\u30022024\u5e747\u670816\u65e5\u306e\u7121\u52b9\u5224\u65ad\u3068\u30012025\u5e7411\u670825\u65e5\u306e\u63a7\u8a34\u5be9\u306b\u3088\u308b\u7834\u68c4\u3002\u6cbb\u7642\u7528\u6297\u4f53\u306e\u9032\u6b69\u6027\u306e\u8a55\u4fa1\u3092Dhenne Avocats\u304c\u89e3\u8aac\u3057\u307e\u3059\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.dhenne-avocats.fr\/ja\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","og_locale":"ja_JP","og_type":"article","og_title":"Action en nullit\u00e9 JUB : Sanofi c. Amgen et les anticorps","og_description":"Premi\u00e8re action en nullit\u00e9 devant la JUB : annulation du 16 juillet 2024 puis infirmation en appel le 25 novembre 2025. Activit\u00e9 inventive des anticorps.","og_url":"https:\/\/www.dhenne-avocats.fr\/ja\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","og_site_name":"Dhenne Avocats","article_published_time":"2024-07-30T10:37:53+00:00","article_modified_time":"2026-10-23T16:32:01+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2026\/10\/og-dhenne-avocats-fr.png","type":"image\/png"}],"author":"Matthieu Dhenne","twitter_card":"summary_large_image","twitter_creator":"@matthieu_dhenne","twitter_site":"@DhenneAvocats","twitter_misc":{"\u57f7\u7b46\u8005":"Matthieu Dhenne","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"13\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/#article","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/"},"author":{"name":"Matthieu Dhenne","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c"},"headline":"Sanofi c. Amgen : la premi\u00e8re action en nullit\u00e9 de la JUB et la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques, de l&rsquo;annulation \u00e0 l&rsquo;infirmation","datePublished":"2024-07-30T10:37:53+00:00","dateModified":"2026-10-23T16:32:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/"},"wordCount":3209,"publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"articleSection":["Brevetabilit\u00e9","JUB","Pharmaceutique"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","url":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/","name":"UPC\u306e\u7121\u52b9\u8a34\u8a1f\uff1aSanofi c. Amgen\u3068\u6297\u4f53\u7279\u8a31","isPartOf":{"@id":"https:\/\/www.dhenne-avocats.fr\/#website"},"datePublished":"2024-07-30T10:37:53+00:00","dateModified":"2026-10-23T16:32:01+00:00","description":"UPC\u306b\u304a\u3051\u308b\u521d\u306e\u7121\u52b9\u8a34\u8a1f\u30022024\u5e747\u670816\u65e5\u306e\u7121\u52b9\u5224\u65ad\u3068\u30012025\u5e7411\u670825\u65e5\u306e\u63a7\u8a34\u5be9\u306b\u3088\u308b\u7834\u68c4\u3002\u6cbb\u7642\u7528\u6297\u4f53\u306e\u9032\u6b69\u6027\u306e\u8a55\u4fa1\u3092Dhenne Avocats\u304c\u89e3\u8aac\u3057\u307e\u3059\u3002","breadcrumb":{"@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.dhenne-avocats.fr\/sanofi-vs-amgen-succes-de-la-premiere-action-en-revocation-de-la-jub-et-evaluation-stricte-de-la-brevetabilite-des-anticorps-therapeutiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.dhenne-avocats.fr\/"},{"@type":"ListItem","position":2,"name":"Sanofi c. Amgen : la premi\u00e8re action en nullit\u00e9 de la JUB et la brevetabilit\u00e9 des anticorps th\u00e9rapeutiques, de l&rsquo;annulation \u00e0 l&rsquo;infirmation"}]},{"@type":"WebSite","@id":"https:\/\/www.dhenne-avocats.fr\/#website","url":"https:\/\/www.dhenne-avocats.fr\/","name":"Dhenne Avocats","description":"\u30d1\u30ea\u306e\u7279\u8a31\u8a34\u8a1f\u30d6\u30c6\u30a3\u30c3\u30af","publisher":{"@id":"https:\/\/www.dhenne-avocats.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.dhenne-avocats.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/www.dhenne-avocats.fr\/#organization","name":"Dhenne Avocats","alternateName":"dhenne avocats","url":"https:\/\/www.dhenne-avocats.fr\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","contentUrl":"https:\/\/www.dhenne-avocats.fr\/wp-content\/uploads\/2024\/03\/cropped-DhenneAvocats_Favicon_RVB_FullColor-1.png","width":512,"height":512,"caption":"Dhenne Avocats"},"image":{"@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DhenneAvocats","https:\/\/www.linkedin.com\/company\/dhenne-avocat\/"]},{"@type":"Person","@id":"https:\/\/www.dhenne-avocats.fr\/#\/schema\/person\/cebb642899b1d41301d41a0187fa329c","name":"\u30de\u30c1\u30e5\u30fc\u30fb\u30c7\u30f3\u30cc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/988db4ff705a27432f0176d0317044da13eaf4eee82d9246f7cf81f2504e05c4?s=96&d=mm&r=g","caption":"Matthieu Dhenne"},"description":"Avocat au barreau de Paris depuis 2014, docteur en droit, fondateur de Dhenne Avocats, cabinet d\u00e9di\u00e9 au contentieux des brevets d\u2019invention. Repr\u00e9sentant devant la Juridiction unifi\u00e9e du brevet. Enseigne le droit de la propri\u00e9t\u00e9 industrielle \u00e0 l\u2019Universit\u00e9 Panth\u00e9on-Assas et assure la correspondance fran\u00e7aise du Kluwer Patent Blog.","sameAs":["https:\/\/www.dhenne-avocats.fr\/equipe-nos-avocats-brevets\/matthieu-dhenne\/","https:\/\/www.linkedin.com\/in\/matthieudhenne\/","https:\/\/x.com\/matthieu_dhenne"]}]}},"_links":{"self":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts\/10242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/comments?post=10242"}],"version-history":[{"count":12,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts\/10242\/revisions"}],"predecessor-version":[{"id":17193,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/posts\/10242\/revisions\/17193"}],"wp:attachment":[{"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/media?parent=10242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/categories?post=10242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dhenne-avocats.fr\/ja\/wp-json\/wp\/v2\/tags?post=10242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}